

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/choosing-an-autoinjector-for-severe-eosinophilic-asthma/12694/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Choosing an Autoinjector for Patients With Severe Eosinophilic Asthma

Reach MD Announcer:

Welcome to ReachMD. This Medical Industry Feature titled, "You Have the Power to Choose," is sponsored by GSK. Intended for US HCP audience only. See full Important Safety Information and Prescribing Information for NUCALA (mepolizumab) in the related content section below. For information on how to use the Autoinjector, please see [NUCALA.com/howto](https://www.nucala.com/howto).

Announcer:

You have the power to choose.

NUCALA (mepolizumab) is indicated for the add-on maintenance treatment for patients 6 years and older with severe eosinophilic asthma.

NUCALA is not indicated for acute bronchospasm or status asthmaticus and should not be administered to those with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Doctor:

I have many different kinds of patients who have many different kinds of needs.

[background tablet noise]

[background typing noise]

[background car noise]

When I'm treating my patients with severe eosinophilic asthma, I need a treatment option that, well, has options.

With NUCALA, I have the Power to Choose between in-office and at-home administration, so I can recommend the option that's the better fit for each and every one of my patients.

Some patients would prefer to continue receiving their injection in the office.

[background typing noise]

[background walking noise]

But other patients may prefer to have options... and administering at home with the Autoinjector could make all the difference.

And that's the beauty of NUCALA. It's one treatment with two administration options, giving you additional ways to meet your patients' needs.

Announcer:

NUCALA may cause hypersensitivity reactions, such as anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, and rash.

Herpes zoster has occurred. Consider vaccination if medically appropriate.

Do not stop systemic or inhaled corticosteroids abruptly.

Treat pre-existing helminth infections before starting NUCALA.

Most common adverse reactions include headache, injection site reactions, back pain, and fatigue.

Data on pregnancy exposures are insufficient to inform on drug-associated risk. A pregnancy registry monitors pregnancy outcomes.

Learn more at NucalaTreatmentOptions.com

Reach MD Announcer:

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

NUCALA injection is available as a 100-mg/mL vial, Autoinjector, and prefilled syringe.

At home administration for patients aged 12 years and older.

This program was sponsored by GSK. If you missed any part of this discussion, visit ReachMD.com/industry-feature. This is ReachMD. Be part of the knowledge.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK or licensor.

MPLAUDI210006 September 2021

Produced in USA.